Table 1.

Pathological and clinical features of 20 LBCL cases with IRF4 rearrangement

Case	Age (y), gender	Biopsy site	Growth pattern	Immunohistochemistry				FISH		COO NanoString (Lymph2Cx)	Stage*	Treatment	Outcome, follow-up
				CD10	BCL6	BCL2	IRF4/MUM1	IRF4	IGH
D1	5, F	LN	Follicular and diffuse	+	+	+	+
D2	14, M	LN	Follicular	+	+	−	+	R		GCB		Surgical excision
D15	5, F	Tonsil	Diffuse	−	+	+	+	R	R	GCB	II	CT-P	CR, 49 mo
D16	14, F	Tonsil	Diffuse	−	+	−	+	R			II	CT-P	CR, 99 mo
D17	21, M	Liver	Diffuse	−	+	+	+	R		ABC	I-E	CT-A	CR, 10 mo †
D20	17, M	Ileum	Diffuse	+	+	+	+	N	R	UNC	II	CT-P	CR, 72 mo
D21	8, M	Tonsil	Follicular	+	+	+	+	R			I	CT-P	CR, 36 mo
D23	21, F	Inguinal LN	Diffuse	−	+		+	R	R	GCB	IV-A	CT-A	CR, 40 mo
D31	12, F	Cervical LN	Diffuse	−	+	+	+	N	R	UNC
D32	7, M	Tonsil	Follicular	+	+	+	+	R		GCB	I	CT-P	CR, 22 mo
D35	6, F	Cervical LN	Diffuse	+	+	−	+	R		GCB	I	CT-P	CR, 63 mo
D46	11, M	Tonsil	Follicular and diffuse	+	+	−	+	R	R	GCB		Surgical excision
D47	22, M	Tonsil	Follicular and diffuse	+	+	−	+	R	R		I	CT-A	CR, 24 mo
D48	18, F	Tonsil	Follicular and diffuse	−	+	−	+	R		UNC	I	CT-A	CR, 29 mo
D50	17, F	Cervical LN	Follicular	−	+	−	+	R	R			Surgical excision
D51	10, F	Tonsil	Follicular and diffuse	+	+	−	+	R		GCB	III	CT-P	CR, 14 mo
D54	18, F	Cervical LN	Diffuse	+	+	+	+	R		GCB	III	CT-P	CR, 14 mo
D62	17, M	Cervical LN	Follicular	−	+	−	+	R		GCB	II	CT-P	CR, 45 mo
D63	14, F	Larynx	Diffuse	+	+	+	+	R		GCB	I	CT-P	CR, 18 mo
D69	15, M	Intestine	Follicular and diffuse	−	+	+	+	R				CT-P	CR, 10 mo

CR, complete response; CT-A, chemotherapy with adult schema protocol (R-CHOP/ESHAP); CT-P, chemotherapy with pediatric schema protocol; F, female; LN, lymph node; M, male; N, normal; R, rearrangement; UNC, intermediate/unclassified.

^*Stage was established according St. Jude/International Pediatric NHL Staging System or Ann Arbor staging system for pediatric and adult patients, respectively.

^†Patients who had a relapse/progression and needed rescue treatment.